Detalhe da pesquisa
1.
CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS.
Blood
; 143(3): 258-271, 2024 Jan 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-37879074
2.
Tafasitamab mediates killing of B-cell non-Hodgkin's lymphoma in combination with γδ T cell or allogeneic NK cell therapy.
Cancer Immunol Immunother
; 71(11): 2829-2836, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-35348812
3.
Activity of tafasitamab in combination with rituximab in subtypes of aggressive lymphoma.
Front Immunol
; 14: 1220558, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37600821
4.
CD19 expression is maintained in DLBCL patients after treatment with tafasitamab plus lenalidomide in the L-MIND study.
Leuk Lymphoma
; 63(2): 468-472, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34779360
5.
α-Radioimmunotherapy with ²¹³Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma.
Oncotarget
; 6(7): 4692-703, 2015 Mar 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-25576914
6.
Macroporous silicon chips for laterally resolved, multi-parametric analysis of epithelial barrier function.
Lab Chip
; 12(13): 2329-36, 2012 Jul 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-22522671
7.
Therapeutic antibodies to human L1CAM: functional characterization and application in a mouse model for ovarian carcinoma.
Cancer Res
; 70(6): 2504-15, 2010 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-20215505
8.
Combinatorial engineering of a gene therapy vector: directed evolution of adeno-associated virus.
J Gene Med
; 8(2): 155-62, 2006 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-16285001
9.
Heparan sulfate proteoglycan binding properties of adeno-associated virus retargeting mutants and consequences for their in vivo tropism.
J Virol
; 80(14): 7265-9, 2006 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-16809332
10.
Green fluorescent protein-tagged adeno-associated virus particles allow the study of cytosolic and nuclear trafficking.
J Virol
; 79(18): 11776-87, 2005 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-16140755